Advertisement
Review Article| Volume 50, ISSUE 1, P229-240, March 2023

Opioids and Opioid Use Disorder in Pregnancy

  • Aalok R. Sanjanwala
    Affiliations
    Department of Obstetrics, Gynecology & Reproductive Sciences, Division of Maternal-Fetal Medicine, University of Pittsburgh School of Medicine, 300 Halket Street Pittsburgh, PA 15213, USA
    Search for articles by this author
  • Grace Lim
    Affiliations
    Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh School of Medicine, 300 Halket Street, Pittsburgh, PA 15213, USA

    Department of Obstetrics, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine, 300 Halket Street, Pittsburgh, PA 15213, USA
    Search for articles by this author
  • Elizabeth E. Krans
    Correspondence
    Corresponding author. Department of Obstetrics, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine, 300 Halket Street, Pittsburgh, PA 15213.
    Affiliations
    Department of Obstetrics, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine, Magee-Womens Research Institute, 300 Halket Street, Pittsburgh, PA 15213, USA
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hirai A.H.
        • Ko J.Y.
        • Owens P.L.
        • et al.
        neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017.
        JAMA. 2021; 325: 146-155
        • Gemmill A.
        • KIANG M.V.
        • Alexander M.J.
        Trends in pregnancy-associated mortality involving opioids in the United States, 2007-2016.
        Am J Obstet Gynecol. 2019; 220: 115-116
        • Ciccarone D.
        The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis.
        Curr Opin Psychiatry. 2021; 34: 344-350
        • CDC
        Three waves of opioid overdose deaths.
        (Availbale at:) (Accessed July 10th, 2022)
        • Ahmad F.B.
        • Cisewski J.A.
        Provisional drug overdose death counts.
        National Center for Health Statistics, Hyattsville (MD)2021
        • Volkow N.D.
        • Frieden T.R.
        • Hyde P.S.
        • et al.
        Medication-assisted therapies--tackling the opioid-overdose epidemic.
        N Engl J Med. 2014; 370: 2063-2066
        • American Society of Addiction Medicine (ASAM)
        national practice guideline for the use of medications in the treatment of addiction involving opioid use.
        (Available at:) (Accessed September, 2022)
        • Wakeman S.E.
        • Larochelle M.R.
        • Ameli O.
        • et al.
        comparative effectiveness of different treatment pathways for opioid use disorder.
        JAMA Netw Open. 2020; 3: e1920622
        • Krans E.E.
        • Kim J.Y.
        • Chen Q.
        • et al.
        Outcomes associated with the use of medications for opioid use disorder during pregnancy.
        Addiction. 2021; 116: 3504-3514
        • Schiff D.M.
        • Nielsen T.
        • Terplan M.
        • et al.
        Fatal and nonfatal overdose among pregnant and postpartum women in massachusetts.
        Obstet Gynecol. 2018; 132: 466-474
        • Djurendic-Brenesel M.
        • Piliga V.
        Opiate receptors and gender and relevance to heroin addiction.
        in: Peter M. Neuropathology of drug addictions and substance misuse. vol 1. Academic Press, Cambridge, Massachusetts2016: 922-932
        • American Society of Addiction Medicine
        Public policy statement: definition of addiction.
        American Society of Addiction Medicine, Chevy Chase (MD)2011 (Available at)
        • McHugh R.K.
        • Devito E.E.
        • Dodd D.
        • et al.
        Gender differences in a clinical trial for prescription opioid dependence.
        J Subst Abuse Treat. 2013; 45: 38-43
        • NIDA
        April 13. Sex and gender differences in substance use disorder treatment.
        (Available at:) (July 7. Accessed)
        • Lewis B.
        • Hoffman L.A.
        • Nixon S.J.
        Sex differences in drug use among polysubstance users.
        Drug Alcohol Depend. 2014; 145: 127-133
        • Liang Y.
        • Goros M.W.
        • Turner B.J.
        Drug overdose: differing risk models for women and men among opioid users with non-cancer pain.
        Pain Med. 2016; 17: 2268-2279
        • McHugh R.K.
        • Votaw V.R.
        • Sugarman D.E.
        • et al.
        Sex and gender differences in substance use disorders.
        Clin Psychol Rev. 2018; 66: 12-23
        • Engstrom M.
        • El-Bassel N.
        • Gilbert L.
        Childhood sexual abuse characteristics, intimate partner violence exposure, and psychological distress among women in methadone treatment.
        J Subst Abuse Treat. 2012; 43: 366-376
        • Pallatino C.
        • Chang J.C.
        • Krans E.E.
        The intersection of intimate partner violence and substance use among women with opioid use disorder.
        Subst Abuse. 2019; 42: 1-8
        • Tsang A.
        • Von Korff M.
        • Lee S.
        • et al.
        Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders.
        J Pain. 2008; 9: 883-891
        • Andersson H.I.
        • Ejlertsson G.
        • Leden I.
        • et al.
        Chronic pain in a geographically defined general population: studies of differences in age, gender, social class, and pain localization.
        Clin J Pain. 1993; 9: 174-182
        • Sullivan M.J.
        • Tripp D.A.
        • Santor D.
        Gender differences in pain and pain behavior: the role of catastrophizing.
        Cognit Ther Res. 2000; 24: 121-134
        • Farrell M.
        Opiate withdrawal.
        Addiction. 1994; 89: 1471-1475
        • Rehni A.K.
        • Jaggi A.S.
        • Singh N.
        Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets.
        CNS Neurol Disord Drug Targets. 2013; 12: 112-125
        • Tompkins D.A.
        • Bigelow G.E.
        • Harrison J.A.
        • et al.
        Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument.
        Drug Alcohol Depend. 2009; 105: 154-159
        • Caritis S.N.
        • Panigrahy A.
        Opioids affect the fetal brain: reframing the detoxification debate.
        Am J Obstet Gynecol. 2019; 221: 602-608
        • Mascola M.A.
        • Borders A.E.
        • Terplan M.
        • et al.
        Opioid use and opioid use disorder in pregnancy.
        Obstet Gynecol. 2017; 130: E81-E94
        • Substance Abuse and Mental Health Services Administration
        Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants.
        Substance Abuse and Mental Health Services Administration, Rockville, MD2018 (HHS Publication No. (SMA) 18-5054)
        • Pizarro D.
        • Habli M.
        • Grier M.
        • et al.
        Higher maternal doses of methadone does not increase neonatal abstinence syndrome.
        J Subst Abuse Treat. 2011; 40: 295-298
        • Cleary B.J.
        • Donnelly J.
        • Strawbridge J.
        • et al.
        Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis.
        Addiction. 2010; 105: 2071-2084
        • McCarthy J.J.
        • Jones H.E.
        • Terplan M.
        • et al.
        Changing outdated methadone regulations that harm pregnant patients.
        J Addict Med. 2021; 15: 93-95
      1. Substance Abuse and Mental Health Services Administration, Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Executive Summary. Publication No. PEP21-02-01-003, 2021, Substance Abuse and Mental Health Services Administration; Rockville, MD.

        • Bednar M.M.
        • Harrigan E.P.
        • Ruskin J.N.
        Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc.
        Am J Cardiol. 2002; 89: 1316-1319
        • Wilder C.
        • Lewis D.
        • Winhusen T.
        Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder.
        Drug Alcohol Depend. 2015; 149: 225-231
        • McCarthy J.J.
        • Leamon M.H.
        • Parr M.S.
        • et al.
        High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes.
        Am J Obstet Gynecol. 2005; 193: 606-610
        • Feghali M.
        • Venkataramanan R.
        • Caritis S.
        Pharmacokinetics of drugs in pregnancy.
        Semin perinatology. 2015; 39: 512-519
        • Jansson L.M.
        • Dipietro J.A.
        • Velez M.
        • et al.
        Maternal methadone dosing schedule and fetal neurobehaviour.
        J Matern Fetal Neonatal Med. 2009; 22: 29-35
        • Wittmann B.K.
        • Segal S.
        A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation.
        Int J Addict. 1991; 26: 213-218
      2. SAMHSA, Split Dose Guidance SOTAs CSAT Final, Available at: https://www.samhsa.gov/sites/default/files/split-dose-guidance-sotas-csat.pdf. Accessed June 2022.

        • Krans E.E.
        • Kim J.Y.
        • James 3rd, A.E.
        • et al.
        Medication-assisted treatment use among pregnant women with opioid use disorder.
        Obstet Gynecol. 2019; 133: 943-951
        • Bastian J.R.
        • Chen H.
        • Zhang H.
        • et al.
        Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.
        Am J Obstet Gynecol. 2017; 216: 64 e1-e64 e7
        • Caritis S.N.
        • Bastian J.R.
        • Zhang H.
        • et al.
        An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy.
        Am J Obstet Gynecol. 2017; 217: 459 e1-e59 e6
      3. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update.
        J Addict Med. 2020; 14: 1
        • Varshneya N.B.
        • Thakrar A.P.
        • Hobelmann J.G.
        • et al.
        Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl.
        J Addict Med. 2021; 16: 265-268
        • Whitley S.D.
        • Sohler N.L.
        • Kunins H.V.
        • et al.
        Factors associated with complicated buprenorphine inductions.
        J Subst Abuse Treat. 2010; 39: 51-57
        • De Aquino J.P.
        • Parida S.
        • Sofuoglu M.
        The pharmacology of buprenorphine microinduction for opioid use disorder.
        Clin Drug Investig. 2021; 41: 425-436
        • Volpe D.A.
        • McMahon Tobin G.A.
        • Mellon R.D.
        • et al.
        Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs.
        Regul Toxicol Pharmacol. 2011; 59: 385-390
        • Galati B.M.
        • Carter E.B.
        • Perez M.
        • et al.
        Buprenorphine patch as a bridge to sublingual treatment of opioid use disorder in pregnancy.
        Obstet Gynecol. 2021; 137: 713-716
        • Towers C.V.
        • Katz E.
        • Weitz B.
        • et al.
        Use of naltrexone in treating opioid use disorder in pregnancy.
        Am J Obstet Gynecol. 2020; 222: 83 e1-e83 e8
        • Wachman E.M.
        • Saia K.
        • Miller M.
        • et al.
        Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
        Clin Ther. 2019; 41: 1681-1689
        • Kelty E.
        • Hulse G.
        A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
        Drugs. 2017; 77: 1211-1219
        • Lee M.
        • Silverman S.M.
        • Hansen H.
        • et al.
        A comprehensive review of opioid-induced hyperalgesia.
        Pain Physician. 2011; 14: 145-161
        • Che X.
        • Cash R.
        • Ng S.K.
        • et al.
        A systematic review of the processes underlying the main and the buffering effect of social support on the experience of pain.
        Clin J Pain. 2018; 34: 1061-1076
        • Mitchell K.D.
        • Smith C.T.
        • Mechling C.
        • et al.
        A review of peripheral nerve blocks for cesarean delivery analgesia.
        Reg Anesth Pain Med. 2019; ([Epub ahead of print])
        • Meyer M.
        • Paranya G.
        • Keefer Norris A.
        • et al.
        Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy.
        Eur J Pain. 2010; 14: 939-943
        • Meyer M.
        • Wagner K.
        • Benvenuto A.
        • et al.
        Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy.
        Obstet Gynecol. 2007; 110: 261-266